144 ·Filed Jun 22, 2026
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral
This routine 10b5-1 plan sale by a director is unlikely to move the stock. Monitor for any unplanned insider sales, but this filing alone does not warrant action.
Final — all horizons settled through T+60d
CGON ▲ +12.76% at T+60d
NEUTRAL call ✓ call won +12.76% · α vs SPY +9.52% · entry $65.73 → $74.12
T+1d
+4.55%
call +4.55% · α +4.60%
$68.72
settled 3mo ago
T+5d
+12.17%
call +12.17% · α +11.16%
$73.73
settled 3mo ago
T+20d
+6.79%
call +6.79% · α +5.63%
$70.19
settled 2mo ago
T+60d
+12.76%
call +12.76% · α +9.52%
$74.12
settled 16d ago
Price Chart
Loading chart...
Executive Summary
CG Oncology director Leonard Post filed a Form 144 indicating intent to sell 6,000 shares (~$366K) under a 10b5-1 plan, likely to exercise stock options. The sale is small relative to market cap ($5.4B) and pre-planned, carrying minimal signal.
Key Facts
- Insider: Leonard E. Post, Director
- Shares to sell: 6,000 common shares
- Estimated value: $366,480 (based on $61.08/share)
- Sale method: Morgan Stanley Smith Barney, pre-arranged 10b5-1 plan
- Acquisition: Upon exercise of stock options over next three months
- Prior sale: 1,000 shares on 06/04/2026 for $54,500
Financial Impact
~$366K, less than 0.01% of market cap
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (22 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006393 |
| Document: 0001950047-26-006393-index.html | 0001950047-26-006393 |
| Document: 0001950047-26-006393.txt | 0001950047-26-006393 |
17 reports for CGON
100% Hit rate best @ T+20▲ +26.33%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Aug 6, 2026 8w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Jul 27, 2026 9w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $67.38 (−7.22%) |
Jul 17, 2026 11w ago | Insider Cluster | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $67.38 (−6.22%) |
Jul 16, 2026 11w ago | Court Ruling | $69.50 $74.71 | ▲ +7.50% | ▲ +3.88% | $67.38 (−3.05%) |
Jun 24, 2026 14w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $67.38 (−7.50%) |
Jun 22, 2026 14w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $67.38 (+2.51%) |
Jun 12, 2026 16w ago | Institutional Cluster | $59.56 $75.24 | ▲ +26.33% | ▲ +24.55% | $67.38 (+13.13%) |
May 26, 2026 18w ago | 8-K | $61.89 $70.25 | ▲ +13.50% | ▲ +15.45% | $67.38 (+8.87%) |
May 15, 2026 20w ago | Press Release | $66.93 $59.56 | ▼ −11.01% | ▼ −13.13% | $67.38 (+0.67%) |
Showing 10 of 17
US Market Status
Market Closed — Opens Mon (39h 28m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access